Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    Ziftomenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 317,847Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kura, Kyowa Kirin Dose First Patient in AML Ph 3 Trial
    Kura, Kyowa Kirin Dose First Patient in AML Ph 3 Trial

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3158094/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-First-Patient-Dosed-in-Pivotal-Phase-3-KOMET-017-Trial-of-Ziftomenib-for-Frontline-Acute-Myeloid-Leukemia-AML.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share
    Kura Oncology, Kyowa Kirin Publish Ziftomenib Data
    Kura Oncology, Kyowa Kirin Publish Ziftomenib Data

    25 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/25/3156758/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-Publication-of-Pivotal-Ziftomenib-Data-in-Relapsed-Refractory-NPM1-Mutated-AML-in-the-Journal-of-Clinical-Oncology.html

    GLOBENEWSWIRE
    25 Sep 2025
    Share Share
    Kura Oncology and Kyowa Kirin Report Positive Data for Ziftomenib
    Kura Oncology and Kyowa Kirin Report Positive Data for Ziftomenib

    12 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/12/3098218/35186/en/Kura-Oncology-and-Kyowa-Kirin-Report-Positive-Updated-Combination-Data-for-Ziftomenib-in-Newly-Diagnosed-AML-at-2025-European-Hematology-Association-Congress.html

    GLOBENEWSWIRE
    12 Jun 2025
    Share Share
    Kura Oncology, Kyowa Kirin Report Positive Ziftomenib Data
    Kura Oncology, Kyowa Kirin Report Positive Ziftomenib Data

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3092389/35186/en/Kura-Oncology-and-Kyowa-Kirin-Report-Positive-Pivotal-Ziftomenib-Monotherapy-Data-at-2025-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Kura Oncology and Kyowa Kirin's Ziftomenib NDA Accepted by FDA
    Kura Oncology and Kyowa Kirin's Ziftomenib NDA Accepted by FDA

    01 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/01/3091510/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Ziftomenib-in-Adults-with-Relapsed-or-Refractory-NPM1-Mutant-AML.html

    GLOBENEWSWIRE
    01 Jun 2025
    Share Share
    Kura Oncology, Kyowa Kirin Present Ziftomenib Data at ASCO
    Kura Oncology, Kyowa Kirin Present Ziftomenib Data at ASCO

    22 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/22/3087182/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-Pivotal-Monotherapy-Data-for-Ziftomenib-in-Oral-Presentation-at-the-2025-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    22 May 2025
    Share Share